In this issue:
Anti-PD-1 vs. anti-CTLA-4 for melanoma
Molecular genetic alterations and RAF fusions in melanoma
Clinical predictors of survival with BRAFV600 -mutated metastatic melanoma
Long-term intracranial outcomes in melanoma and non-small cell lung cancer
AI-based decision support in the diagnosis of melanoma
FDG PET/CT imaging one week after a single dose of pembrolizumab
Neoadjuvant dual checkpoint inhibitors vs anti-PD1 therapy
Recurrence-free and overall survival for patients with stage II melanoma
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Does patient sex affect the treatment outcome of ICIs?
Please login below to download this issue (PDF)